Meta description The PERCC pilot trial tests a precise behavioral exercise regimen for stage II non small cell lung cancer and signals regulatory considerations for potential device oriented development. Publication date context: February 19, 2026. A pilot trial named PERCC tests a precise exercise regimen for cancer care in patients with stage II non small cell lung cancer. The intervention is described as behavioral, and the study is sponsored by the Dana-Farber Cancer Institute. The record indicates not yet recruiting. The trial page uses a URL that includes the term medical device, which adds regulatory context even though the intervention is described as behavioral in the provided text. This article explains what is known and why it matters for clinical practice and regulatory planning.
What is PERCC and how is the trial designed?
PERCC stands for Precise Exercise Regimen for Cancer Care. The record describes the intervention as behavioral rather than device related. The target population is adults with stage II non small cell lung cancer. The sponsor is the Dana-Farber Cancer Institute. The study status is not recruiting. The trial page uses a URL that includes the term medical device, which adds regulatory context for future classification while the text describes the intervention as behavioral in the extract. As a pilot study this record signals exploratory work rather than a large scale trial. Specific design details such as randomization or endpoints are not provided in the extract. The information available supports a focus on feasibility, acceptability and potential signals of benefit from a structured exercise approach in this patient group.
What does the PERCC program involve?
The description indicates a behavioral intervention in a cancer care setting. The exact components, delivery method and frequency are not listed in the provided text. The label PERCC suggests a carefully tailored regimen, but the details would be defined in a final protocol and any future public postings.
Are there safety and regulatory considerations?
Even though the intervention is described as behavioral, the inclusion of medical device in the URL triggers attention to regulatory pathways that may apply if a device is later associated with the regimen or its delivery. The MDR style requires a clear statement of intended use and safety considerations for devices. For now the record describes a behavioral intervention and not a device claim.
Who is the target population and what is the intervention in practice?
The setting is stage II lung cancer in the non small cell category. This broad category includes NSCLC cases. The intervention is described as a behavioral regimen termed PERCC. The relationship between the cancer diagnosis and the exercise program is defined in plain language by the sponsor in the source text. Practitioners and stakeholders should note the trial status is not recruiting at present. The sponsor is a major cancer center, and this fact supports credibility for future regulatory submissions if data support a device or software based solution tied to the regimen.
Who qualifies for the trial and what is the intervention in practice?
The text identifies the patient group as adults with stage II NSCLC. It does not provide detailed inclusion or exclusion criteria. The intervention remains described as behavioral, not a device. Regulatory teams will need final protocol language to define practical aspects of delivery and monitoring.
What is the regulatory context and potential impact for medical devices?
The source work centers on cancer care with a behavioral focus. The inclusion of a medical device term in the link underscores the need for formal regulatory consideration should a device or software component be introduced later. The MDR framework requires a defined intended use statement, performance data and safety safeguards. At present the record does not claim device based performance and should be monitored for updates from the sponsor and trial registry.
What are the immediate regulatory implications for practitioners?
Clinical teams and regulatory professionals should track the official protocol and postings to understand if this program shifts toward a device oriented solution. Any future descriptions of the PERCC regimen that include device elements would require conformity assessment and clear safety and performance claims in line with MDR rules.
What outcomes are expected and what is the evidence basis?
Because this is a pilot trial the primary aim is typically to evaluate feasibility and acceptability of the regimen in a real world cancer care setting. The official text does not list endpoints. In regulatory discourse this information guides decision making on future trials and any product development associated with the regimen. Clinicians may look for signals that the regimen improves functional status or quality of life in stage II NSCLC patients.
FAQ
- What is PERCC and what is the aim Describe a behavioral exercise regimen in cancer care that focuses on stage II NSCLC.
- What is the study status The trial is listed as not yet recruiting.
- Who sponsors this work The Dana-Farber Cancer Institute is listed as the sponsor.
- Where can the primary trial information be found The ClinicalTrials.gov entry for NCT07412041 is provided with the source text.
Conclusion and implications for readers
This pilot study points to an exploratory path in which a behavioral exercise regimen could be part of future cancer care. Regulatory teams should watch for protocol updates and for data that could inform any device oriented development. Clinicians should prepare for future guidance on how such a regimen might be integrated with standard NSCLC care.
Disclaimer
This article is written for professionals. It is not legal advice. It provides context based on the source text and is not a substitute for regulatory counsel. Readers should consult official regulatory authorities for guidance.